MedTrace Logo

DFN-02 Open Label Safety Study in Patients With Acute Migraine

NCT02279082 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines

Conditions

  • Acute Migraine

Interventions

DRUG

DFN-02

Active Experimental Drug

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02279082 on ClinicalTrials.gov